B. Metzler seel. Sohn & Co. Holding AG Invests $1.90 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 33,183 shares of the biopharmaceutical company's stock, valued at approximately $1,899,000.

A number of other hedge funds have also recently made changes to their positions in HALO. US Bancorp DE boosted its position in shares of Halozyme Therapeutics by 64.6% during the 1st quarter. US Bancorp DE now owns 13,912 shares of the biopharmaceutical company's stock worth $566,000 after purchasing an additional 5,458 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Halozyme Therapeutics by 9.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 41,550 shares of the biopharmaceutical company's stock worth $1,587,000 after purchasing an additional 3,500 shares during the period. O Shaughnessy Asset Management LLC boosted its position in shares of Halozyme Therapeutics by 4.6% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 12,067 shares of the biopharmaceutical company's stock worth $491,000 after purchasing an additional 536 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in Halozyme Therapeutics by 29.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company's stock valued at $5,321,000 after buying an additional 29,845 shares during the period. Finally, Shell Asset Management Co. boosted its position in Halozyme Therapeutics by 30.4% in the 1st quarter. Shell Asset Management Co. now owns 11,199 shares of the biopharmaceutical company's stock valued at $456,000 after buying an additional 2,611 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total value of $590,900.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares of the company's stock, valued at approximately $39,988,802.96. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 60,000 shares of company stock valued at $3,425,000 over the last ninety days. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO traded up $3.30 on Friday, reaching $49.00. The company had a trading volume of 4,549,535 shares, compared to its average volume of 1,368,916. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The stock has a market capitalization of $6.23 billion, a PE ratio of 16.18, a P/E/G ratio of 0.41 and a beta of 1.29. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a 50-day moving average price of $54.85 and a 200-day moving average price of $53.42.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HALO. TD Cowen raised their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. HC Wainwright reissued a "buy" rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday. Wells Fargo & Company cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price target for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Cowen reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, Benchmark reissued a "buy" rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.